M8W.F · MediWound Ltd
-
-
| Sector | Healthcare |
|---|---|
| ISIN | IL0011316309 |
| CurrencyCode | EUR |
| Exchange | F |
| Industry | Biotechnology |
| Beta | 0.98 |
|---|---|
| Dividend Yield | 0.0% |
| PE Ratio | None |
| Market Cap | 111M |
| Target Price | 6.92 |
ABOUT
MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Learn More